Ayako Watanabe

Ayako Watanabe

Auto-generated profile, based on publicly available information

Ayako Watanabe

Department of Pharmacy Showa University Koto Toyosu Hospital Tokyo Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2023 in Clinical Case Reports
Verified
Journal Article
Open access
TNTakuya Nagata
Takuya Nagata
AWAyako Watanabe
Ayako Watanabe
KMKenji Momo
Kenji Momo
YKYuka Kashiwabara
Yuka Kashiwabara
MSMisa Saeki
Misa Saeki
KTKatsumi Tanaka
Katsumi Tanaka
Key Clinical Message: We present a case of chemotherapy‐induced hiccups that were alleviated by steroid rotation. Hiccups are often overlooked, but they have an impact on the patient's quality of life. In the COVID‐19 era, web‐based teleworking has become an important tool, hiccups during a teleconference should be noted as a concern for patients.

5 December 2021 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
AWAyako Watanabe
Ayako Watanabe
KMKenji Momo
Kenji Momo
KTKatsumi Tanaka
Katsumi Tanaka
TNTakuya Nagata
Takuya Nagata
RKRemi Kuchira
Remi Kuchira
TSTadanori Sasaki
Tadanori Sasaki
Gemcitabine induce thrombocytopenia and thrombocytosis as toxicity. In this report, we show detailed time‐course for platelet fluctuation. Our case emphasis attention to monitor see‐saw‐like toxicity on platelet count.

1 August 2023 in Drugs - Real World Outcomes
Verified
Journal Article
Open access
PDF file
HKHiromi Koshizuka
Hiromi Koshizuka
KMKenji Momo
Kenji Momo
AWAyako Watanabe
Ayako Watanabe
AMAiri Matsuzaki
Airi Matsuzaki
YKYuka Kashiwabara
Yuka Kashiwabara
TSTadanori Sasaki
Tadanori Sasaki
Background Several oral drugs are recommended to be taken with large amounts of water for reasons such as peptic ulcer prophylaxis. On the other hand, there are many patients with diseases that restrict water intake, and the actual frequency of patients receiving prescriptions in these conflicting situations is not clear. Objective Using a large claims database in Japan, this study aimed to determine the proportion of patients aged ≥ 75 years on fluid restriction who received drugs whose drug package insert mentioned “a large amount of water intake is needed when taking the drug”. Methods We performed a prescription survey of older patients over 75 years of age using the Japan Medical Data Centre (JMDC) claims database. Out of approximately 8800 oral drugs used in Japan, we defined 29 drugs for which package inserts noted that a large amount of water intake is recommended during drug administration. We defined diagnosis codes for some common diseases for which restricted water intake is likely recommended: heart failure (NYHA class III or IV), liver cirrhosis with ascites, and chronic kidney disease stage 5, including dialysis patients. Results Of 5968 patients aged ≥ 75 years (men 47.7%), 320 (5.4%) patients with heart failure (2.8%, n = 170), liver cirrhosis (0.7%, n = 40), or chronic kidney disease (1.9%, n = 113), diagnoses likely associated with the need for fluid restriction, were prescribed drugs for which abundant fluid at intake was recommended. Among 29 identified drugs, 15 drugs were administered to older patients over 75 years with fluid restriction due to said diseases. Conclusions Of patients 75 years and older with disease likely requiring water restriction, 5.4% faced the dilemma of following advice to restrict fluid intake due to their diagnoses or to adhere to instructions in drug package inserts to have abundant fluid intake when taking the drug. Our study raises awareness regarding the dilemma of water restriction and intake in clinical settings, highlighting the importance of considering individual patient needs. These real-world findings emphasize the need for information and guidelines to assist healthcare professionals in navigating this dilemma and making informed decisions for the benefit of their patients.

2 June 2024 in Clinical Case Reports
Verified
Journal Article
Open access
TITatsuki Iha
Tatsuki Iha
AWAyako Watanabe
Ayako Watanabe
MSMisa Saeki
Misa Saeki
AIAyaka Itoh
Ayaka Itoh
YKYuka Kashiwabara
Yuka Kashiwabara
KMKenji Momo
Kenji Momo
Key Clinical Message: An 86‐year‐old geriatric patient with sepsis presented cibenzoline‐induced hypoglycaemia, although within the boundary range of cibenzoline blood concentration. An 86‐year‐old geriatric patient taking cibenzoline for ametropic hypertrophic cardiac tendinopathy was admitted to our hospital for the treatment of sepsis. Upon admission, blood cibenzoline levels of 400.1 ng/mL were observed. Antibiotic therapy was initiated and cibenzoline was discontinued. On Day 16, cibenzoline was administered orally at a reduced dose of 50 mg/day. Several days after restarting cibenzoline, the patient developed hypoglycaemia (64 mg/dL), prompting the administration of 20% glucose. The present case demonstrates a rational timeline for cibenzoline administration, considering the patient's renal dysfunction and sepsis. Clinicians should exercise caution when managing older patients with severe infections who are receiving cibenzoline, and should consider the possibility of blood glucose fluctuations regardless of cibenzoline blood levels. Further research is warranted to better understand and address the potential side effects of cibenzoline administration in geriatric populations.

3 September 2023 in Clinical Case Reports
Verified
Journal Article
Open access
MSMisa Saeki
Misa Saeki
AWAyako Watanabe
Ayako Watanabe
KMKenji Momo
Kenji Momo
YKYuka Kashiwabara
Yuka Kashiwabara
TITatsuki Iha
Tatsuki Iha
KTKatsumi Tanaka
Katsumi Tanaka
Key Clinical Message: A 97‐year‐old woman with gastrostomy had a drastic enhancement for PT‐INR after starting antibiotic therapy. Possible causes include (1) vitamin K deficiency due to fasting and (2) a combination of warfarin and antibiotics. Geriatric and Asian‐descent patients are more sensitive to the effects of warfarin, a key anticoagulant drug. In this report, we present a 97‐year‐old bedridden woman being treated with warfarin for cardiogenic cerebral infarction and femoral neck replacement as part of in‐home medical care with a gastrostomy and was admitted to our hospital after developing pneumonia. We discontinued warfarin and started antibiotics, and her pneumonia‐related symptoms improved. Eleven days after restarting warfarin, the patient's PT‐INR surpassed the upper limit for measurement (over 10). We considered the mechanism might be triggered by (1) fasting, low nutrition status; and (2) antibiotics secondary to risk factors such as gastrostomy and being a super‐geriatric woman. We recommend careful monitoring of PT‐INR in patients treated with warfarin and antibiotics, especially in the setting of gastrostomy or older persons.

28 January 2024 in Clinical Case Reports
Verified
Journal Article
Open access
YKYuuri Kurokawa
Yuuri Kurokawa
AWAyako Watanabe
Ayako Watanabe
YKYuka Kashiwabara
Yuka Kashiwabara
SFSaori Fukuda
Saori Fukuda
SNShohei Nomoto
Shohei Nomoto
KMKenji Momo
Kenji Momo
Key Clinical Message: Most drugs that cause adverse events are difficult to identify in critically ill patients undergoing polypharmacy. We share our experience in identifying the causative drug among four suspect drugs administered during emergency treatment. We present the case of a 93‐year‐old man who was admitted for the treatment of cerebrovascular events. The patient was initially prescribed dual antiplatelet therapy with aspirin and clopidogrel along with lansoprazole, Hange‐koboku‐toh, and elobixibat. On day 36 after admission, the patient was found to have developed agranulocytosis. To improve his cerebrovascular prognosis, we first discontinued medications other than the anticoagulant medicines and initiated filgrastim. We discontinued clopidogrel 9 days after the discontinuation of the other medicines considering his low white blood cell count. One day after the discontinuation of clopidogrel, the agranulocytosis was alleviated. Considering the time course, clopidogrel, lansoprazole, Hange‐koboku‐toh, and elobixibat were suspected as the culprit medicines. This case highlights the considerable challenges encountered in clinical practice when attempting to identify the drugs responsible for agranulocytosis, particularly in patients on intensive medication therapy.